Intra-Cellular Therapies Gross Profit 2013-2022 | ITCI
Intra-Cellular Therapies annual/quarterly gross profit history and growth rate from 2013 to 2022. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
- Intra-Cellular Therapies gross profit for the quarter ending March 31, 2022 was $0.032B, a 120.77% increase year-over-year.
- Intra-Cellular Therapies gross profit for the twelve months ending March 31, 2022 was $0.093B, a 171.47% increase year-over-year.
- Intra-Cellular Therapies annual gross profit for 2021 was $0.076B, a 262.21% increase from 2020.
- Intra-Cellular Therapies annual gross profit for 2020 was $0.021B, a 34191.8% increase from 2019.
- Intra-Cellular Therapies annual gross profit for 2019 was $0B, a INF% increase from 2018.
Intra-Cellular Therapies Annual Gross Profit
(Millions of US $) |
| 2021 |
$76 |
| 2020 |
$21 |
| 2019 |
$0 |
| 2018 |
$ |
| 2017 |
$0 |
| 2016 |
$0 |
| 2015 |
$0 |
| 2014 |
$1 |
| 2013 |
$3 |
| 2012 |
$3 |
Intra-Cellular Therapies Quarterly Gross Profit
(Millions of US $) |
| 2022-03-31 |
$32 |
| 2021-12-31 |
$23 |
| 2021-09-30 |
$20 |
| 2021-06-30 |
$18 |
| 2021-03-31 |
$14 |
| 2020-12-31 |
$11 |
| 2020-09-30 |
$7 |
| 2020-06-30 |
$2 |
| 2020-03-31 |
$1 |
| 2019-12-31 |
|
| 2019-09-30 |
|
| 2019-06-30 |
|
| 2019-03-31 |
|
| 2018-12-31 |
|
| 2018-09-30 |
|
| 2018-06-30 |
|
| 2018-03-31 |
|
| 2017-12-31 |
$0 |
| 2017-09-30 |
$0 |
| 2017-06-30 |
$0 |
| 2017-03-31 |
$0 |
| 2016-12-31 |
$0 |
| 2016-09-30 |
$0 |
| 2016-06-30 |
$0 |
| 2016-03-31 |
|
| 2015-12-31 |
$0 |
| 2015-09-30 |
|
| 2015-06-30 |
$0 |
| 2015-03-31 |
$0 |
| 2014-12-31 |
$0 |
| 2014-09-30 |
$0 |
| 2014-06-30 |
$0 |
| 2014-03-31 |
$0 |
| 2013-12-31 |
$1 |
| 2013-09-30 |
$1 |
| 2013-06-30 |
$1 |
| 2013-03-31 |
$1 |
| 2012-12-31 |
|
| 2012-09-30 |
$0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$5.459B |
$0.084B |
|
Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York.
|
